Form 4: BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, Reports Stock Transactions
SEC Form 4 Filing
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions involving common stock and restricted stock units (RSUs).
- On June 14, 2024, and June 15, 2024, Yocca acquired 521 and 562 shares of common stock, respectively, through the vesting of RSUs.
- On June 17, 2024, Yocca disposed of 372 shares of common stock at a price of $1.28 per share.
- Following these transactions, Yocca beneficially owns 13,474 shares of common stock.
- Yocca also holds 3,648 and 6,188 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is a common occurrence in the pharmaceutical industry. Investors often monitor these filings for insights into management's perspective on the company's stock and future prospects.
Comparison to Industry Standards
- Insider trading activity is a common metric followed across the pharmaceutical industry.
- Comparing Yocca's transactions to those of executives at similar-sized biotech companies like Madrigal Pharmaceuticals or Viking Therapeutics could provide context.
- However, without additional context on BioXcel's performance and industry trends, it's difficult to assess the significance of these transactions relative to industry benchmarks.
Stakeholder Impact
- The reported transactions may have a minor impact on shareholders' perception of the company's stock.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| December 14, 2023 | Rule 10b5-1 trading plan adopted |
| March 15, 2023 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| June 14, 2024 | Acquisition of 521 shares of common stock through RSU vesting. |
| June 15, 2024 | Acquisition of 562 shares of common stock through RSU vesting. |
| June 17, 2024 | Disposal of 372 shares of common stock at $1.28 per share. |
| June 18, 2024 | Date of Form 4 filing. |
Keywords
Form 4, BioXcel Therapeutics, BTAI, Frank Yocca, Chief Scientific Officer, Stock Transactions, Beneficial Ownership, Restricted Stock Units, RSU, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.